Last reviewed · How we verify
NCT04984538
Implementation of a Pharmacist-led Pharmacogenomic Clinical Service
trial testing Pharmacogenomic Testing in Adverse Drug Event. Withdrawn.
30 January 2023
Quick facts
| Lead sponsor | Tabula Rasa HealthCare |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 1 July 2021 |
| Primary completion | 30 January 2023 |
| Estimated completion | 30 January 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Pharmacogenomic Testing
Conditions studied
- Adverse Drug Event — all drugs for Adverse Drug Event →
- Drug Drug Interaction — all drugs for Drug Drug Interaction →
- Pharmacogenomics — all drugs for Pharmacogenomics →
- Elderly — all drugs for Elderly →
Sponsor
Tabula Rasa HealthCare — full company profile →
Who can join
18 and older, any sex, with Adverse Drug Event or Drug Drug Interaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tabula Rasa HealthCare (TRHC), doing business as CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services. CareKinesis utilizes medication decision support tools and pharmacists certified in geriatrics to provide pharmacy services for various healthcare organizations including PACE organizations (described above). Presently, CareKinesis services more than 35 PACE organizations, including approximately 100 PACE sites, across the United States. As a national PACE pharmacy provider since 2011, CareKinesis focuses on improving medication regimens to reduce medication-related risks while enhancing economic, clinical and humanistic outcomes. Pharmacist-led PGx clinical services and medication safety reviews are currently being offered to PACE organizations under the direction of licensed healthcare prescribers by TRHC (CareKinesis). Our aim is to extend and meticulously study PGx testing for more PACE patients and conduct a prospective preemptive PGx study to determine feasibility of implementation and effect on outcomes. After mutual agreement, these services may also be extended to other organizations where TRHC provides pharmacy services, and data will be collected with patient consent.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04984538
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pharmacogenomic Testing
Trials testing the same drug.
- NCT05053815 — Pharmacogenomic Testing in a Program of All-inclusive Care for the Elderly (PACE) Setting · unknown
- NCT03591224 — Pharmacogenomic Testing to Optimize Antidepressant Drug Therapy · NA · completed
- NCT02932579 — Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes · Phase 4 · terminated
Other recruiting trials for Adverse Drug Event
Currently open trials in the same condition.
- NCT06575530 — Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients · Phase 4 · recruiting
- NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting
- NCT07164300 — Comparative Study of Tranexamic Acid Dosing in Cardiac Surgery · NA · recruiting
- NCT05084196 — Melatonin for Prevention of Kidney Injury · Phase 3 · recruiting
- NCT05717712 — Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma · Phase 1 · recruiting
Other Tabula Rasa HealthCare trials
Trials by the same sponsor.
- NCT05346770 — Pharmacist-led Interventions to Improve Medication Use · unknown
- NCT05053815 — Pharmacogenomic Testing in a Program of All-inclusive Care for the Elderly (PACE) Setting · unknown
- NCT05053828 — Type 2 Diabetes With Antiplatelet Drugs · completed
- NCT04971902 — Pharmacist-led Pharmacogenomic Clinical Service Within the Program of All-inclusive Care for the Elderly · unknown
- NCT04288193 — Implementation of a Pharmacist-Driven Antipsychotic Deprescribing Initiative in the PACE Setting: A Pilot Study · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04984538 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tabula Rasa HealthCare
- Last refreshed: 1 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04984538.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing